Literature DB >> 16496231

Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer.

Ulrika Broomé1, Annika Bergquist.   

Abstract

The prevalence of inflammatory bowel disease (IBD) in patients with PSC differs in various part of the world. Ulcerative colitis (UC) is most common, but 1 to 14% of all primary sclerosing cholangitis (PSC) patients have Crohn disease with colonic involvement. Many PSC patients without clinical symptoms of IBD have colonoscopic and histological findings compatible with IBD, and the subclinical phase may last several years before onset of symptoms of active colitis. The characteristics of UC in patients with PSC are different from those in UC patients without PSC. The colitis is usually substantial, the clinical course of the colitis is quiescent, and rectal sparing is common. Moreover, PSC patients with UC have a higher risk of developing colorectal dysplasia/carcinoma than UC patients without PSC. In patients having an ileal pelvic pouch with ileal anal anastomosis, PSC is a risk factor for development of pouchitis. It is important that all PSC patients with UC are included in colonoscopic surveillance programs.

Entities:  

Mesh:

Year:  2006        PMID: 16496231     DOI: 10.1055/s-2006-933561

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  48 in total

Review 1.  Dysplasia and colitis.

Authors:  Robert Enns; Brian Bressler
Journal:  Can J Gastroenterol       Date:  2009-05       Impact factor: 3.522

Review 2.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 3.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 4.  Extraintestinal manifestations and complications in IBD.

Authors:  Claudia Ott; Jürgen Schölmerich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

5.  Hepatopancreatobiliary manifestations of inflammatory bowel disease.

Authors:  Kazuhiko Nakamura; Tetsuhide Ito; Kazuhiro Kotoh; Eikichi Ihara; Haruei Ogino; Tsutomu Iwasa; Yoshimasa Tanaka; Yoichiro Iboshi; Ryoichi Takayanagi
Journal:  Clin J Gastroenterol       Date:  2012-01-06

6.  Pan-colonic field defects are detected by CGH in the colons of UC patients with dysplasia/cancer.

Authors:  Lisa A Lai; Rosa Ana Risques; Mary P Bronner; Peter S Rabinovitch; David Crispin; Ru Chen; Teresa A Brentnall
Journal:  Cancer Lett       Date:  2012-03-02       Impact factor: 8.679

7.  A Review of Inflammatory Bowel Disease in the Setting of Liver Transplantation.

Authors:  Veena Nannegari; Saenz Roque; David T Rubin; Rodrigo Quera
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

8.  The association between pulmonary function impairment and colon inflammation in ulcerative colitis patients: A scientific basis for exterior-interior correlation between lung and large intestine.

Authors:  Jian-Yun Wang; Xin-Yue Wang; Hua-Yang Wu; Hui-Yi Sun; Da-Ming Liu; Wen Zhang; Chen-Xi Jin; Shuo-Ren Wang
Journal:  Chin J Integr Med       Date:  2014-06-18       Impact factor: 1.978

9.  Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.

Authors:  Johannes R Hov; Verena Keitel; Jon K Laerdahl; Lina Spomer; Eva Ellinghaus; Abdou ElSharawy; Espen Melum; Kirsten M Boberg; Thomas Manke; Tobias Balschun; Christoph Schramm; Annika Bergquist; Tobias Weismüller; Daniel Gotthardt; Christian Rust; Liesbet Henckaerts; Clive M Onnie; Rinse K Weersma; Martina Sterneck; Andreas Teufel; Heiko Runz; Adolf Stiehl; Cyriel Y Ponsioen; Cisca Wijmenga; Morten H Vatn; Pieter C F Stokkers; Severine Vermeire; Christopher G Mathew; Benedicte A Lie; Ulrich Beuers; Michael P Manns; Stefan Schreiber; Erik Schrumpf; Dieter Häussinger; Andre Franke; Tom H Karlsen
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

10.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.